Sunshine Biopharma (SBFM) Net Equity Issued and Repurchased (2010 - 2024)

Sunshine Biopharma's Net Equity Issued and Repurchased history runs 10 years deep, the most recent figure standing at $8.5 million for Q1 2024.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $8.5 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $8.5 million (up 108.41% YoY) and the FY2025 annual result came in at $1.8 million, down 78.54% from the prior year.
• Net Equity Issued and Repurchased was $8.5 million for Q1 2024 at Sunshine Biopharma, up from $10.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $29.1 million in Q2 2022 and bottomed at -$13.2 million in Q4 2022.
• A 3-year average of $7.2 million and a median of $6.3 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 85.96% in 2023, while the deepest fall reached 85.96% in 2023.
• Sunshine Biopharma's Net Equity Issued and Repurchased stood at -$13.2 million in 2022, then jumped by 100.0% to $10.0 in 2023, then surged by 85224010.0% to $8.5 million in 2024.
• Business Quant data shows SBFM's Net Equity Issued and Repurchased at $8.5 million in Q1 2024, $10.0 in Q3 2023, and $4.1 million in Q2 2023.